NCT06981234 - Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Type 1 Diabetes

Interventions

DRUG

Acetazolamide

Acetazolamide is a potent carbonic anhydrase inhibitor that acts on the renal proximal tubule. Through this mechanism, it inhibits proximal tubule sodium reabsorption.

DRUG

Placebo

Standard pharmaceutical filler will be capsulated and packaged identically to the acetazolamide.

Trial Locations (1)

92037

RECRUITING

UC San Diego Altman Clinical & Translational Research Institute, La Jolla